Literature DB >> 14647497

Modifying quinolone antibiotics yields new anxiolytics.

Timothy B C Johnstone1, Derk J Hogenkamp, Leanne Coyne, Jiping Su, Robert F Halliwell, Minhtam B Tran, Ryan F Yoshimura, Wen-Yen Li, Jeff Wang, Kelvin W Gee.   

Abstract

Patients taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and anxiety. These side effects probably result from antagonism of the neurotransmitter gamma-aminobutyric acid (GABA) at the brain GABA(A) receptor complex (GRC). Modification of norfloxacin yields molecules such as compound 4 that potentiate GABA action with alpha(2) subunit selectivity. Compound 4 is anxiolytic but does not cause sedation, and may represent a new class of ligands that have anxiolytic activity without sedative liability.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14647497     DOI： 10.1038/nm967

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  10 in total

Review 1.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

2.  Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Authors:  Herman J Ng; Edward R Whittemore; Minhtam B Tran; Derk J Hogenkamp; Ron S Broide; Timothy B Johnstone; Lijun Zheng; Karen E Stevens; Kelvin W Gee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

3.  Modifications of diflunisal and meclofenamate carboxyl groups affect their allosteric effects on GABAA receptor ligand binding.

Authors:  Mikko Uusi-Oukari; Laura Vähätalo; Arto Liljeblad
Journal:  Neurochem Res       Date:  2014-06-13       Impact factor: 3.996

4.  Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

Authors:  John R Atack; Peter H Hutson; Neil Collinson; George Marshall; Graham Bentley; Christopher Moyes; Susan M Cook; Ian Collins; Keith Wafford; Ruth M McKernan; Gerard R Dawson
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 5.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

6.  Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

Authors:  A Lippa; P Czobor; J Stark; B Beer; E Kostakis; M Gravielle; S Bandyopadhyay; S J Russek; T T Gibbs; D H Farb; P Skolnick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

7.  Clinical characteristics and outcomes of antibiotic-associated encephalopathy in patients with end-stage kidney disease.

Authors:  Qingxiu Huang; Jianbo Li; Naya Huang; Xi Xia; Yagui Qiu; Zhong Zhong; Zhenchuan Lin; Xiaowen Huang; Dihua Zhang; Fengxian Huang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 8.  Nicotinic receptor-based therapeutics and candidates for smoking cessation.

Authors:  Linda P Dwoskin; Andrew M Smith; Thomas E Wooters; Zhenfa Zhang; Peter A Crooks; Michael T Bardo
Journal:  Biochem Pharmacol       Date:  2009-06-10       Impact factor: 5.858

Review 9.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

10.  Positive allosteric modulators of nonbenzodiazepine γ-aminobutyric acidA receptor subtypes for the treatment of chronic pain.

Authors:  Timothy B C Johnstone; Jennifer Y Xie; Chaoling Qu; David J Wasiak; Derk J Hogenkamp; Frank Porreca; Kelvin W Gee
Journal:  Pain       Date:  2019-01       Impact factor: 7.926
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.